Atorvastatin

Generic Name: Atorvastatin

Brand Names: Atorvaliq, Caduet, Lipitor, Lypqozet

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₅FN_₂O_₅

CAS Number: 134523-00-5

Unique Ingredient Identifier: A0JWA85V8F

Background: Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylg...

Indication: Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.
...

Associated Conditions: Anginal Pain, Cardiovascular Complications, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Coronary artery thrombosis, Dysbetalipoproteinemia, Fredrickson Type III lipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hospitalizations, Hypertension, Essential Hypertension, Hypertriglyceridemias, Mixed Dyslipidemias, Mixed Hyperlipidemia, Myocardial Infarction, Non-familial hypercholesterolemia, Nonfatal Myocardial Infarction, Postoperative Thromboembolism, Primary Hypercholesterolemia, Stroke, Thrombosis, Transient Ischemic Attack, Elevation of serum triglyceride levels, Heterozygous familial hyperlipidemia, Non-familial hyperlipidemia, Primary Hyperlipidemia, Revascularization procedures

Associated Therapies: -

Clinical Trials

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

Phase 2

Terminated

Conditions: Anatomic Stage III Breast Cancer AJCC v8
HER2/Neu Negative
Anatomic Stage IIB Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Inflammatory Breast Carcinoma
Estrogen Receptor Negative
Anatomic Stage IIIB Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Progesterone Receptor Negative
Prognostic Stage IIB Breast Cancer AJCC v8

Interventions: Drug: Atorvastatin
Drug: Capecitabine

First Posted Date: 2019-03-13

Last Posted Date: 2024-10-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT03872388

Locations: 🇺🇸
Banner - MD Anderson Cancer Center -Northern Colorado, Greeley, Colorado, United States
🇺🇸
Cooper Hospital University Medical Center, Camden, New Jersey, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

and more 2 locations

Comparison of Carvedilol and Atorvastatin for Preventing of Contrast-Induced Nephropathy.

Phase 2

Completed

Conditions: Contrast-induced Nephropathy

Interventions: Drug: Atorvastatin
Drug: Carvedilol
Drug: saline

First Posted Date: 2019-03-08

Last Posted Date: 2019-03-12

Lead Sponsor: rabab ahmed mohamed

Target Recruit Count: 144

Registration Number: NCT03867994

Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Atorvastatin
Drug: Ezetimibe
Drug: Placebo for Ezetimibe
Drug: Placebo for Atorvastatin

First Posted Date: 2019-03-07

Last Posted Date: 2024-05-10

Lead Sponsor: Organon and Co

Target Recruit Count: 621

Registration Number: NCT03867318

Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer

Phase 2

Completed

Conditions: Erectile Dysfunction, CTCAE
Male Erectile Disorder
Prostate Adenocarcinoma
Impotence

Interventions: Drug: Atorvastatin
Drug: Pentoxifylline
Dietary Supplement: Vitamin E Compound

First Posted Date: 2019-02-05

Last Posted Date: 2023-10-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT03830164

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin

Phase 3

Terminated

Conditions: Acute Chest Syndrome

Interventions: Drug: Atorvastatin
Drug: Placebo Aspirin
Drug: Aspirin
Drug: Placebo Atorvastatin

First Posted Date: 2019-01-29

Last Posted Date: 2022-05-24

Lead Sponsor: Dr. med. Mahir Karakas

Target Recruit Count: 68

Registration Number: NCT03820466

Locations: 🇩🇪
University of Leipzig, Leipzig, Germany
🇩🇪
University of Berlin, Campus Benjamin-Franklin, Berlin, Germany
🇩🇪
University Heart Center Hamburg, Hamburg, Germany

and more 4 locations

Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer

Phase 3

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: Acetylsalicylic acid
Drug: Atorvastatin

First Posted Date: 2019-01-28

Last Posted Date: 2024-11-29

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 1210

Registration Number: NCT03819101

Locations: 🇨🇭
Kantonsspital Baden, Baden, Switzerland
🇨🇭
Bellinzona Istituto Oncologico, Bellinzona, Switzerland
🇨🇭
Kantonsspital Baselland, Bruderholz, Switzerland

and more 17 locations

Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin

Phase 1

Completed

Conditions: Drug Interaction Potentiation

Interventions: Drug: Vadadustat
Drug: Rosuvastatin
Drug: Pravastatin
Drug: Simvastatin
Drug: Atorvastatin
Drug: Sulfasalazine

First Posted Date: 2019-01-11

Last Posted Date: 2019-03-22

Lead Sponsor: Akebia Therapeutics

Target Recruit Count: 134

Registration Number: NCT03801733

Locations: 🇨🇦
InVentiv Health Clinique Inc., Québec City, Quebec, Canada

Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Combination Product: EZ 10 mg/Ator 10 mg
Drug: Atorvastatin
Combination Product: EZ 10 mg/Ator 20 mg
Drug: Placebo for FDC EZ/Ator
Drug: Placebo for atorvastatin

First Posted Date: 2018-12-07

Last Posted Date: 2024-05-16

Lead Sponsor: Organon and Co

Target Recruit Count: 454

Registration Number: NCT03768427

Locations: 🇨🇳
Central People s Hospital of Siping ( Site 0046), Siping, Jilin, China
🇨🇳
The First Affiliated Hospital of Baotou Medical College ( Site 0025), Baotou, Anhui, China
🇨🇳
Chongqing General Hospital ( Site 0037), Chongqing, Chongqing, China

and more 27 locations